Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 160 (ZNF160) is a Kruppel-related zinc finger transcription factor characterized by an N-terminal KRAB (Kruppel-associated box) domain, which imparts strong transcriptional repression activity[1][2][7]. ZNF160 binds DNA to regulate gene expression, including epigenetic silencing through histone deacetylation and DNA methylation by recruiting scaffold proteins like KAP1 and associated chromatin modifiers[2]. It is involved in transcriptional regulation processes, including modulating inflammatory responses in intestinal epithelial cells by repressing TLR4 gene transcription, thus maintaining immune homeostasis[2]. Although encoded as a protein-coding gene with several transcript variants, ZNF160 is not currently recognized as a direct therapeutic target (receptor, enzyme, transporter, etc.), nor are there known interacting drugs or reported safety concerns[1][2][7]. Disease association is minimal, with limited reports linking it to patellar chondromalacia[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 160 (ZNF160).